Keywords: GlaxoSmithKline, ChemoCentryx, Traficet-EN, Inflammatory bowel syndrome, Crohn's disease
GlaxoSmithKline exercises option for ChemoCentryx’ Traficet-EN for IBD
Article | 12 January 2010
As part of a deal signed in 2006, UK drug giant GlaxoSmithKline has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease, licensed from USA-based ChemoCentryx.
T Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
